Background: Clinical diagnosis of frontotemporal dementia (FTD) can be challenging, requiring an accurate tool dedicated to this diagnostic hurdle. Since FTD exhibits distinct regional atrophy patterns on magnetic resonance imaging (MRI), AI-aided automated brain volume analysis could enhance the clinical diagnostic assessment of FTD, including the detection of the disease and the classification of subtypes, which encompass behavioral variant (BV), semantic variant (SV), and progressive non-fluent aphasia (PNFA). In this study, we leverage automated brain volumetry software to approach both FTD detection and the differential diagnosis among its subtypes.
Method: A total 258 patients with FTD (BV = 57, SV = 40, PNFA = 34) and 127 Normal Control (NC) were identified from the frontotemporal lobar degeneration neuroimaging initiative (NIFD) data sets with available MRI. We obtained 104 areas of patient's normalized regional brain volumes using VUNO-Med DeepBrain. Comparative analyses were conducted to explore differences in regional volume distribution between FTD and NC, as well as among FTD subtype based on their known atrophy patterns. Additionally, regional normative percentiles were utilized as features for classification using the XGBoost algorithm to distinguish FTD vs NC, BV vs SV vs PNFA, and BV vs SV vs PNFA vs NC.
Result: In BV, significant differences in atrophy patterns were observed in the frontal lobe, demonstrating an anterior-posterior gradient compared to SV, PNFA and NC (P<0.01). SV exhibited left side dominant asymmetric atrophy, particularly in the inferior temporal lobe, compared to BV, PNFA, and NC (P<0.01). Additionally, the inferior horn of the lateral ventricle in SV had higher volume than other subtypes, attributable to atrophy of surrounding brain regions. In contrast, the differences in atrophy patterns for PNFA were statistically less significant when compared to other FTD subtypes. Automated brain volumetry software-based classifications demonstrated high accuracy of FTD vs NC (Accuracy 95% CI = [0.88, 0.89]), BV vs SV vs PNFA ([0.79, 0.81]), and BV vs SV vs PNFA vs NC ([0.82, 0.83]).
Conclusion: Our study demonstrates the effectiveness of automated brain volumetry and machine learning in identifying FTD and differentiating frontotemporal dementia subtypes, contributing to an enhanced understanding of subtypes and improved diagnostic precision in neurodegenerative disorders.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/alz.086728 | DOI Listing |
Zhong Nan Da Xue Xue Bao Yi Xue Ban
August 2024
Department of Neurology, Second Xiangya Hospital, Central South University, Changsha 410011.
Methylenetetrahydrofolate reductase (MTHFR) deficiency is a rare autosomal recessive genetic disorder caused by mutations in the gene, leading to a variety of clinical manifestations. In October 2022, the Second Xiangya Hospital of Central South University admitted a 21-year-old male patient with neuropsychiatric disorders, presenting primarily with cognitive decline, limb tremors, abnormal mental and behavioral symptoms, seizures, and gait disturbances. These symptoms had gradually developed over 5 years, worsening significantly in the past year.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Neurology Department Infanta Leonor Hospital, Madrid, Spain.
Background: biomarkers are essential in order to make a diagnosis with a high level of accuracy in patients with cognitive and behavior complaints. However, molecular imaging biomarkers not always provide an answer in daily clinical practice.
Methods: retrospective and descriptive study in patients with Amyloid PET (APscans) implemented according to rational use of this technic, between January 2019-November 2023 in Neurology Department, Infanta Leonor Hospital, Madrid, Spain.
Background: The Amyloid-Tau-Neurodegeneration (ATN) biomarker framework for Alzheimer's disease (AD) indicates binary (presence/absence) designations for each type of pathology, without regard for anatomical distribution. Neurodegeneration is designated as positive if atrophy or hypometabolism are found on imaging. However, Clifford Jack et al.
View Article and Find Full Text PDFBackground: Reactive astrogliosis refers to functional and morphological changes in astrocytes that occur with neuronal damage in numerous neurological conditions. PET tracers targeting monoamine oxidase B (MAO-B) are used to visualize reactive astrogliosis in the living brain. [F]SMBT-1, a MAO-B selective PET tracer, was developed by modifying the chemical structure of [F]THK5351.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
German Center for Neurodegenerative Diseases (DZNE), Rostock, Germany.
Background: Speech abnormalities are increasingly recognized as a manifestation of cognitive deficits in Alzheimer's disease (AD) and its preclinical and prodromal stages. Here, we investigated whether MRI measures of brain atrophy, specifically in the basal forebrain and cortical language areas, can predict cognitive decline and speech difficulties in older adults within the AD spectrum.
Method: The ongoing Prospect-AD study aims to develop an algorithm to automatically identify speech biomarkers in individuals with early signs of AD.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!